MyFinsight
Home
Blog
About
Contact
Download
Download image
Redemption of marketable
debt securities
$165,871K
Proceeds from the
exercise of stock options
$632K
Proceeds from issuance of
common stock under espp
$108K
Proceeds from issuance of
common stock and...
$2K
Net cash provided by
(used in) investing...
$58,857K
Net cash provided by
financing activities
$594K
Canceled cashflow
$107,014K
Canceled cashflow
$148K
Net increase
(decrease) in cash, cash...
-$4,051K
Canceled cashflow
$59,451K
Stock-based compensation
$11,801K
Accounts payable
$6,026K
Depreciation and
amortization
$4,511K
Non-cash operating lease
expense
$824K
Prepaid expenses and
other current assets
-$261K
Purchase of marketable
debt securities
$107,005K
Purchase of property and
equipment
$9K
Tax withholding
payments related to net...
$148K
Net cash used in
operating activities
-$63,502K
Canceled cashflow
$23,423K
Revenues
$13,858K
Other segment income
$6,185K
Net loss
-$79,621K
Canceled cashflow
$20,043K
Accretion of discount on
marketable debt securities
$2,960K
Accrued expenses and
other current...
-$2,823K
Operating lease
liabilities
-$1,450K
Other
$71K
Total costs and
operating expenses
$98,278K
Income tax expense
(benefit)
$1,386K
Total research and
development expenses
$73,696K
Total general and
administrative expenses
$22,194K
Cost of revenues
$2,388K
Clinical Product
Candidates
$25,901K
Clinical Product
Manufacturing
$19,694K
Personnel Related
Expenses Excluding Stock...
$15,711K
Other
$7,415K
Stock Based
Compensation
$3,156K
Depreciation And
Amortization
$1,819K
Stock Based
Compensation
$8,645K
Personnel Related
Expenses Excluding Stock...
$5,235K
Professional And Consultant
Fees
$4,179K
Other
$4,135K
Back
Back
Cash Flow
source: myfinsight.com
Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS)